Get Answers When a Loss Occurs

More than 50% of first trimester miscarriages are caused by chromosomal abnormalities. Anora looks at tissue from a pregnancy loss (also called "products of conception" or "POC") to find out if a chromosome abnormality was the likely cause of the miscarriage. The results of Anora can reduce a patient's emotional burden caused by a miscarriage by helping to explain why it occurred. It can also help identify if there is an increased chance for the patient to have another pregnancy with a chromosome problem.

Anora can be used on losses that occur as early as five weeks and can even be used to test previous miscarriages if the tissue was stored in paraffin.


Clinically Effective POC

Anora is validated to detect whole chromosome aneuploidy, triploidy, tetraploidy (detectable in the 3:1 form), uniparental disomy, and deletions and duplications greater than 5 Mb. Terminal deletions or duplications and clinically significant deletions and duplications down to 1 Mb are also reported.

Anora's key features, include:

  • About a one-week turnaround
  • No cell culture needed; thus, no cell culture failure
  • <1% chance of test failure
  • A small (pea-sized) amount of tissue required
  • Detection of maternal cell contamination without needing to order a separate test
  • Detection of complete uniparental disomy and triploidy
  • Ability to determine parent of origin of abnormality
  • Paraffin POC testing can be performed for previous losses

Benefits of Anora

Anora uses chromosomal microarray analysis featuring single nucleotide polymorphism (SNP) technology. This provides more comprehensive results across all chromosomes than standard karyotyping and array CGH.

The Anora miscarriage test:

  • Offers higher detection rates than many other POC tests available
  • Increases the likelihood of actionable results for patients
  • Decreases wait time and increases the likelihood of meaningful results
  • Identifies cases at high risk of molar pregnancy and increased risk for maternal gestational trophoblastic disease
  • Simplifies the collection process
  • Provides answers to more patients
Back to Top